


A decorative graphic on the left side of the slide consisting of numerous red blood cells of various sizes, some appearing to float and others clustered together, creating a sense of movement and biological focus.

13th Annual European Medtech and Healthcare Services Conference

Goldman Sachs
London, September 8th, 2016


STRATEC AT A GLANCE



- Market leader in automation solutions for the diagnostics industry and translational research
- ~ 950 employees worldwide
- More than 13,000 systems installed globally
(e.g. DiaSorin's LIAISON XL | Hologic/Gen-Probe's PANTHER | Siemens' ADVIA Centaur | bioMérieux's new VIDAS)
- Revenue € 146.9 million in 2015
(CAGR revenues since IPO: ~18%)
- Revenue growth forecasted to € 175 - € 182 million in 2016
- Dividend payments raised over 12 consecutive years

UNIQUE MARKET POSITION

STRATEC IN THE IVD VALUE CHAIN



BUSINESS MODEL

STRATEC provides instrumentation, consumables, software and automation solutions

- OEM development and manufacturing
- More than 2,300 fully automated analyzer systems manufactured in 2015
- Wide range of intellectual property rights

Extensive collaboration with partner during design phase

- STRATEC: Engineering / automation, software, QM
- Partner: System / reagent / market requirements

Systems have long market lifecycles

- Leads to longstanding partnerships
- Expanding installed base of systems
- Product enhancement and extension drives value



Consumable for “Simoa HD-I”



Simoa HD-1 Analyzer Prototype

“Simoa HD-I” for Quanterix

SECURING RETURN ON INVESTMENT

Long-term agreements with partners

- Milestone payments during development stage
- Operating sales during series production stage
- Continuous revenues from consumable sales

Minimum volume commitment

- Firm purchase orders
- STRATEC an integral part of partners' plans

Reliable partnership

- Shortened development time
- Integration of analyzer system and reagents
- Agreed development budget & transfer price
- High commitment by both partners




“PANTHER” for Hologic




“LIAISON XL” for DiaSorin

EXPANDING THE LAB AUTOMATION VALUE CHAIN




DIATRON – EXPANDING THE VALUE CHAIN




IVD MARKET SEGMENTS / IVD Market: ~ 50 billion USD in 2015

Market by product type



Market by sector



CAGR 2013 - 2018:

IVD Market: 4%

Molecular Diagnostic: 8%
Hematology: 2 %


Immunodiagnosics: 4%
Blood bank: 6 %

Source: The worldwide market for In Vitro Diagnostic Tests, 9th Edition.

A SELECTION OF STRATEC CUSTOMERS

GLOBAL TOP 20 IVD COMPANIES		Revenues 2014 (USD billion)
1.	Roche Diagnostics	8.9
2.	Danaher	5.0
3.	SIEMENS	4.8
4.	Abbott Diagnostics	4.7
5.	Thermo Fisher	3.3
6.	Alere	2.3
7.	Ortho Clinical Diagnostics	1.9
8.	Sysmex	1.9
9.	bioMerieux	1.7
10.	BIO-RAD	1.4
11.	BECTON DICKINSON	1.3
12.	Hologic / Gen-Probe	1.2
13.	CH Werfen	1.0
14.	Grifols (incl. Novartis diagnostics business unit)	0.8
15.	QIAGEN	0.7
16.	Diagnostica Stago	0.6
17.	DiaSorin	0.6
18.	Agilent / Dako	0.6
19.	EUROIMMUN	~0.4
20.	Immucor	~0.4


Source: IVD News / figures adjusted by acquisitions in 2012 / non-public companies estimated / non-reported sector revenues estimated

... AND OTHER GAME-CHANGING COMPANIES





SALES

6-Months Sales compared to Annual Sales



6M/2016 Sales


- +11.5% to € 78.0 Mio.
- Diatron: €10.5 Mio. in Q2

Q2/2016 Sales organically

- +2.6% to € 36.3 Mio.
(Q2/2015: € 35.5 Mio.)

EBIT & EBIT MARGIN

As of June 30




EBIT margin picking up:

- Reinstating economies of scale in Q2
- Q2/2016 (organic): 17.5% +16 bps (Q2/2015:17.3%)
- 6M/2016: 16.2% / - 95 bps (6M/2015: 17.1%)

¹ figures exclude non-recurring special effects

EARNINGS AFTER SIX MONTHS

Earnings per share as of June 30



- Adjusted EPS at € 0.87 (6M/2015: € 0.83)
- Adjusted 6M tax rate at 15.9% (6M/2015: 19.2%)
- Dividend pay out per share at € 0.75 (previous year: € 0.70)

¹ figures exclude non-recurring special effects

FOCUS IN 2016

Business Development	Revenue Growth	Profitability and Cash Flow
<ul style="list-style-type: none"> • Successful Integration of Diatron and STRATEC Cosumables • M&A Opportunities • Further extend development and manufacturing capacities • Sign new projects 	<ul style="list-style-type: none"> • Product launches and ramp-ups • Development projects • Revenues from new business 	<ul style="list-style-type: none"> • Diatron and STRATEC Consumables: Integration cost, investments and synergy effects • Efficiency improvements • Continue to build up consumable business • Reduction of working capital

FINANCIAL GUIDANCE

	FY 2016	FY 2017
Revenues	175 - 182 € million	205 - 220 € million
EBIT-Margin	16.0 % - 17.5 %	Slight growth compared to 2016

Organic growth (excluding Diatron and STRATEC Consumables acquisitions):
CAGR ~6 % for 2016 and 2017

CONTACT

STRATEC Biomedical AG

Gewerbestr. 37
75217 Birkenfeld
Germany

Tel: +49 7082 7916-0

Fax: +49 7082 7916-999

www.stratec.com

ir@stratec.com

TICKER

Symbol: SBS.DE

Bloomberg: SBS:GR

Reuters: SBSG.DE

ISIN: DE000STRA555

WKN: STRA55

SAFE HARBOR STATEMENT

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this.

This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.

THANK **YOU**
FOR **YOUR**
ATTENTION!